{
  "report_rows": [
    {
      "kpi": "Adjusted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$1.90 vs. cons $1.84",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue",
      "prediction": "IN-LINE",
      "answer": "pred ~$100.8B vs. cons $100.09B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Health Care Benefits medical benefit ratio",
      "prediction": "BEAT",
      "answer": "pred ~89.0% vs. cons 90.1%",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adjusted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$7.40-$7.60 vs. cons $7.46 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Health Care Benefits adjusted operating income guidance",
      "prediction": "BETTER",
      "answer": "guide ~$4.15B-$4.49B vs. cons $4.30B (FY2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "Medical benefit ratio guidance",
      "prediction": "BETTER",
      "answer": "guide ~90.0% vs. cons 90.3% (FY2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "Operating cash flow guidance",
      "prediction": "BETTER",
      "answer": "guide ~$10.0B vs. cons $9.8B (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.2,
  "day5_path": "FADE",
  "day5_rationale": "Aetna cost performance and a modest FY2026 raise should drive the initial upside, but the raise is likely concentrated in Q2 and reserve/current-year favorability rather than materially higher second-half earnings. With the stock already pricing in a strong recovery, limited upward revision to implied Q3-Q4 and 2027 estimates should cause part of the day-1 move to fade.",
  "day5_confidence": "MEDIUM"
}